NCT04137562View on ClinicalTrials.gov

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

December 11, 2019

Primary Completion Date

January 26, 2023

Study Completion Date

October 31, 2027

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

ADSTEM Inj.

Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10\^8 cells/5mL

OTHER

Placebo

330mL of 0.9% normal saline is injected intravenously twice for the duration of the study.

Trial Locations (6)

Unknown

Chungnam National University Hospital, Daejeon

Korea University AnSan Hospital, Ansan

Chung-Ang University Hospital, Seoul

Kyunghee University Medical Center, Seoul

Seoul National University Hospital, Seoul

SMG-SNU Boramae Medical Center, Seoul

All Listed Sponsors
lead

EHL Bio Co., Ltd.

INDUSTRY

NCT04137562 - Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis | Biotech Hunter | Biotech Hunter